Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

References

• Kaminski MS, Tuck M, Estes J, . 131I-tositumomab therapy as initial therapy for follicular lymphoma. N Engl J Med 2005;352:441–9.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, . Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–7573.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Gordon LI, Multani PS, . Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia:a phase II multicenter trial. Blood 2002;99:4336–4342.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, . Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab- refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262–3269.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, . Randomized controlled trial of ytrrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–2463.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Russo SM, Tepper JE, Baldwin AS Jr, . Enhancement of radiosensitivity by proteasome inhibition:implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183–193.
   PubMed Web of Science ®Google Scholar
• Cusack JC Jr, Liu R, Houston M, . Enhanced chemosensitivity to CPT-11 with proteosome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 2001;61:3535–3540.
   PubMed Web of Science ®Google Scholar
• Pervan M, Calimlim J, Matso D, . Active comibination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model. Blood 2005;106(Suppl. 1): Abstract 2406.
   Google Scholar
• Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002;21:3898–3908.
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Portlock C, Moskowitz C, . Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Hematol 2009;146:652–655.
   PubMed Web of Science ®Google Scholar
• DiBella N, Taetle R, Kolibaba K, . Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475–480.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Portlock C, Moskowitz C, . Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;6:719–726.
   Web of Science ®Google Scholar
• Craig M, Hanna WT, Cabanillas F, . Bortezomib in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma: results of a phase 2 study. Blood 2010;116(Suppl. 1): Abstract 2798.
   Google Scholar
• Coiffier B, Osmanov EA, Hong X, . Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma:a randomised phase 3 trial. Lancet Oncol 2011;12:773–784.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, . The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Fowler N, Kahl BS, Lee P, . Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma:the phase II VERTICAL study. J Clin Oncol 2011;29:3389–3395.
   PubMed Web of Science ®Google Scholar
• deVos S, Goy A, Dakhil SR, . Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27:5023–5030.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Enrico O, Gabriele B, Nadia C, . Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138:396–397.
   PubMed Web of Science ®Google Scholar
• Nowis D, Maczewski M, Mackiewicz U, . Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658–2668.
   PubMed Web of Science ®Google Scholar
• Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004;4:230–237.
   PubMedGoogle Scholar
• O’Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005;6:191–199.
   PubMedGoogle Scholar
• Baiocchi RA, Alinari L, Lustberg ME, . Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer2010 Dec 14. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Gandolfi L, Stenfoni V, . Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk 2010;10:258–261.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, . Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–3803.
   PubMed Web of Science ®Google Scholar
• Beaven AW, Shea TC, Moore DT, . A phase I study evaluating ibritumomab tiuxetan (Zevalin) in combination with bortezomib (Velcade) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lympoma 2012;53:254–258.
   PubMed Web of Science ®Google Scholar